Sara Mainardi

TL;DR: The data identify SHP2 inhibition as an unexpected vulnerability of KRAS-mutant NSCLC cells that remains undetected in cell culture and can be exploited therapeutically and combined inhibition of SHp2 and MEK is an effective therapeutic approach in non-small-cell lung cancer.

TL;DR: Using multiple in vivo mouse models of liver cancer, treatment with combined inhibition of of CDC7 and mTOR results in a marked reduction of tumour growth, indicating that exploiting an induced vulnerability could be an effective treatment for liver cancer.

TL;DR: K-RAS oncogene-driven lung adenocarcinomas is one of the most malignant human tumors for which there are no efficacious therapeutic strategies, and a mouse tumor model that closely recapitulates this human disease is used to illustrate that adult lung cells are uniquely sensitive to transformation by this Oncogene.

TL;DR: A one-two punch approach for the treatment of cancer in which a drug is first used to induce senescence in cancer cells and a second drug is then used to kill senescent cancer cells is proposed.

TL;DR: It is shown that a small subset of miRNAs is differentially expressed in APL and modulated by ATRA-based treatment.